<DOC>
	<DOCNO>NCT01018953</DOCNO>
	<brief_summary>The purpose protocol ass efficacy safety BIM 23A760 patient 's overall satisfaction term symptom relief ( diarrhoea and/or flush ) patient carcinoid syndrome 24 week treatment .</brief_summary>
	<brief_title>Study Assess Efficacy Safety Different Doses BIM 23A760 Patients With Carcinoid Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Serotonin Syndrome</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>The patient carcinoid syndrome define ≥3 stools/day and/or ≥3 flushes/week . The patient elevate 5Hydroxyindoleacetic acid ( upper limit normal ) . The patient welldifferentiated midgut carcinoid tumour serotonin secrete tumour unknown localisation hepatic metastasis . The patient undergone surgery related neuroendocrine tumour ( NET ) within 4 week prior study entry surgery plan study . The patient receive short act somatostatin analogue ( SSAs ) within 2 week study entry receive short act SSAs 3 month . The patient receive radiolabelled SSA time study entry . The patient receive long acting SSAs certain circumstance . The patient previously receive specific anti tumour treatment chemotherapy , ( chemo ) embolisation , radiotherapy interferon last 6 month . The patient sign symptom cardiac insufficiency . The patient ejection fraction &lt; 40 % and/or clinically severe cardiac valvular regurgitation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>